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Melatonin is an ancient molecule which was first identified in the 
late 1950s [1]. It exists in almost every organism starting from the 
primitive ones as prokaryotes to the very complex organisms as the 
humans. Melatonin is known as a circadian rhythm regulator [2]. This 
indoleamide is a neurohormone considered classically to be secreted by 
the pineal gland, nonetheless, it is currently known to be synthesized 
in other organs and tissues such as the retina and cerebellum [3,4], 
iris, ciliary body [5], crystalline lens [6,7], Harderian gland [8] and the 
lacrimal gland [9], spleen, heart, skeletal muscle, liver, stomach, gut, 
placenta, testes, ovaries, cerebral cortex and striatum [10].
Melatonin levels in the body are variable giving the time of the 
day, it increases at night and when light enters the eye and reach the 
retina, melatonin is suppressed [11], such photoreception being due to 
specific ganglion cells in the retina containing the pigment melanopsin 
[12]. This neurohormone is of great importance in the eye, apart from 
the retina it has numerous functions, such as working as an antioxidant 
protecting ocular structures against free radicals. For instance, melatonin 
intraperitoneal injection on rats instantly following an oxidative stress 
has shown to protect the lens against cataract [13]. Melatonin is inversely 
related to intraocular pressure since IOP decreases at night while 
melatonin increases [14]. It also has been proved to reduce intraocular 
pressure (IOP) by decreasing the rate of aqueous humour secretion by 
the non-pigmented ciliary epithelium, resulting in a modulation of IOP 
[15]. More importantly, melatonin is important for the cornea. Studies 
showed that melatonin accelerate corneal wound healing, and it has 
been possible to demonstrate that the effect of melatonin is to increase 
the rate of cell migration rather than mitosis [16]. Besides, melatonin 
has the ability to potentiate the effect of diadenosine tetraphosphate, a 
tear secretion inducer, being suitable to treat one of the most prevalent 
ocular conditions: Dry eye [17].
Treating ocular conditions have many challenges due to poor drug 
delivery because of effective multiple barriers to drug entry, comprising 
nasolacrimal drainage, epithelial drug transport barriers and clearance 
from the vasculature in the conjunctiva [18]. While topical ocular 
bioavailability is extraordinary poor, in the order of 5% or less, sustained 
delivery systems for diseases of the posterior segment such as various 
vitreoretinal disorders through intraocular delivery systems are used 
via implantable devices or injections [19]. However, independently of 
the fact that intraocular drug delivery systems are invasive, up to date, 
long-term drug delivery for diseases of the anterior segment of the eye 
does not exist.
There are several ways for drugs to reach the ocular system, for 
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instance, melatonin orally administered at a concentration of 10 mg 
to patients before performing cataract surgery have shown to lower 
intraocular pressure, consequently, they had better operating condition 
[20]. Melatonin was also investigated for the treatment of uveitis in 
hamsters, experiments were done by injecting 5 mg of melatonin before 
the induction of uveitis, and results suggested that melatonin prevents 
the clinical and biochemical consequences of this disorder [21]. 
Among several factors leading to poor bioavailability of drug 
administered topically, the cornea is the primary barrier of the anterior 
segment due to lipophilicity and tight junctions which restrain the 
entrance of pharmacological substances [22]. In this sense, experiments 
have demonstrated that when melatonin or any of its analogues is 
topically applied, the amount that appears within the eye was between 
3 and 4 orders of magnitude lower than the instilled amount [23]. This 
relevant fact is suggesting that it is necessary to improve the delivery 
ways to permit better results with less amount of melatonin. 
There are three main ideas that can be highlighted: One can be to 
facilitate the entrance through the cornea by modifying the barrier effect. 
Second, to permit melatonin to remain longer on the ocular surface to 
allow a slow but a sustained entrance of this substance. Third to induce 
the intraocular synthesis of melatonin by modulating light wavelength.
Concerning the first idea, an interesting study showed that the 
molecule diadenosine tetraphosphate (Ap4A), has the ability to make 
transiently disappear the corneal tight junctions permitting efficient 
drug delivery to the eye. A study showed that 5-MCA-NAT, a melatonin 
analog, had more hypotensive effect when instilled topically on New 
Zealand white rabbits when diadenosine tetraphosphate was applied 
two hours before the melatonin analogue. Indeed, when 5-MCA-
NAT was topically applied after using diadenosine tetraphosphate, the 
amount of this melatonin analogue found within the eye was 3-fold the 
one measured when it was instilled alone [24]. This is indicating that 
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the transient elimination of the corneal tight junctions is an effective 
mechanism to permit the entrance of molecules into the eye [25].
The second idea consists of permitting melatonin to remain longer 
on the ocular surface. A possible alternative for a long-term drug 
delivery is the use of contact lenses, in such a way, ocular bioavailability 
will be improved considering reduced tear mixing between the lens 
and the cornea besides the extended drug release [26]. The traditional 
method is to soak the lens in drug solution in order for the drug to be 
absorbed into the polymeric lenses, this way permits limited and slow 
release of the drugs into the post-lens lacrimal fluid [18,27]. Melatonin 
and analogues can be soaked in contact lenses overnight and the lenses 
can be fitted to obtain a sustained release of these substances. In this 
way, when melatonin is topically instilled it lasted no more than 2 min 
on the ocular surface as happens with all compounds applied in this way 
[18]. When melatonin and analogues are released from contact lenses 
the maximal release occurs 2 hours after the lens fitting, their presence 
being measurable for more than 300 min, as it happens with other 
naturally occurring substances [27]. This slow but sustained release of 
melatonin will permit the entry of this substance and therefore a more 
robust intraocular effect. 
The third idea is based on modifying the light that enters the eye in 
order to induce the natural production of melatonin in the lens, instead 
of applying it exogenously. Recently, it has been possible to describe 
the presence of melanopsin in the lens epithelium [28]. This pigment 
abolishes the synthesis of melatonin when the lens is illuminated with 
blue light (including the blue component of white light). Therefore, it 
is possible to induce the synthesis of melatonin by reducing the blue 
component of white light (460-490 nm wavelength) by means of filters. 
Interestingly, white light permits a discrete synthesis of melatonin 
in lens epithelial cells (about 20 pmol/106 cells), but the blockade of 
blue light permits levels which are 3-fold higher (60 pmol/106 cells) 
[28]. This regulation of the local synthesis of melatonin by filtering 
light, could be an interesting approach to induce melatonin synthesis 
intraocularly and to help in processes such as the reduction of IOP and 
cataract prevention. 
In summary, melatonin has proven effective for several ocular 
disorders and it could be interesting to investigate the best possible way 
for its delivery giving the challenges ophthalmologists are facing due to 
limited non-invasive drug delivery systems to the eye.
Acknowledgements
This work was supported by grants from Ministerio de Economía y 
Competitividad [SAF2013-44416-R] and [SAF2016-77084R], and Ministerio de 
Sanidad RETICS [RD12/0034/0003] and [RD16/0008/0017]. Hanan A. Alkozi is a 
fellowship holder of Saudi Arabia government.
References
1. Lerner AB, Case JD, Takahashi Y (1960) Isolation of melatonin and 
5-methoxyindole-3-acetic acid from bovine pineal glands. J Biol Chem 235: 
1992-1997.
2. Brennan R, Jan JE, Lyons CJ (2007) Light, dark, and melatonin: emerging 
evidence for the importance of melatonin in ocular physiology. Eye 21: 901-908.
3. Bubenik GA, Brown GM, Uhlir I, Grota LJ (1974) Immunohistological localization 
of N-acetylindolealkylamines in pineal gland, retina and cerebellum. Brain Res 
81: 233-242.
4. Stefulj J, Hortner M, Ghosh M, Schauenstein K, Rinner I, et al. (2001) Gene 
expression of the key enzymes of melatonin synthesis in extrapineal tissues of 
the rat. J Pineal Res 30: 243-247.
5. Aimoto T, Rohde BH, Chiou GC, Lauber JK (1985) N-acetyltransferase activity 
and melatonin level in the eyes of glaucomatous chickens. J Ocul Pharmacol 
1: 149-160.
6. Quay WB (1984) Increases in volume, fluid content, and lens weight of eyes 
following systemic administration of melatonin. J Pineal Res 1: 3-13.
7. Abe M, Itoh MT, Miyata M, Shimizu K, Sumi Y (2000) Circadian rhythm of 
serotonin N-acetyltransferase activity in rat lens. Exp Eye Res 70: 805-808.
8. Djeridane Y, Vivien‐Roels B, Simonneaux V, Miguez JM, Pévet P (1998) 
Evidence for melatonin synthesis in rodent Harderian gland: a dynamic in vitro 
study. J Pineal Res 25: 54-64.
9. Mhatre MC, van Jaarsveld AS, Reiter RJ (1988) Melatonin in the lacrimal gland: 
first demonstration and experimental manipulation. Biochem Biophys Res 
Commun 153: 1186-1192.
10. Sánchez‐Hidalgo M, Guerrero Montávez, JM, Carrascosa‐Salmoral MDP, 
Naranjo Gutierrez MDC, Lardone PJ (2009) Decreased MT1 and MT2 melatonin 
receptor expression in extrapineal tissues of the rat during physiological aging. 
J Pineal Res 46: 29-35.
11. Arendt J, Aldhous M, Wright J (1988) Synchronisation of a disturbed sleep-
wake cycle in a blind man by melatonin treatment. Lancet 331: 772-773.
12. Doyle SE, Castrucci AM, McCall M, Provencio I, Menaker M (2006) Nonvisual 
light responses in the Rpe65 knockout mouse: rod loss restores sensitivity to 
the melanopsin system. Proc Natl Acad Sci 103: 10432-10437. 
13. Bardak Y, Özertürk Y, Özgüner F, Durmus M, Delibas N (2000) Effect of 
melatonin against oxidative stress in ultraviolet-B exposed rat lens. Curr Eye 
Res 20: 225-230. 
14. Fan S, Agrawal A, Gulati V, Neely DG, Toris CB (2014) Daytime and nighttime 
effects of brimonidine on IOP and aqueous humor dynamics in participants with 
ocular hypertension. J Glaucoma 23: 276.
15. Wiechmann AF, Wirsig-Wiechmann CR (2001) Melatonin receptor mRNA and 
protein expression in Xenopus laevis nonpigmented ciliary epithelial cells. Exp 
Eye Res 73: 617-623.
16. Crooke A, Guzman-Aranguez A, Mediero A, Alarma-Estrany P, Carracedo G, 
et al. (2015) Effect of melatonin and analogues on corneal wound healing: 
Involvement of Mt2 melatonin receptor. Curr Eye Res 40: 56-65.
17. Hoyle CH, A Peral, J Pintor (2006) Melatonin potentiates tear secretion induced 
by diadenosine tetraphosphate in the rabbit. Eur J Pharmacol 552: 159-161.
18. Kompella UB, Kadam RS, Lee VH (2010) Recent advances in ophthalmic drug 
delivery. Ther Deliv 1: 435-456.
19. Kuno N, Fujii S (2010) Biodegradable intraocular therapies for retinal disorders: 
progress to date. Drugs Aging 27: 117-134.
20. Ismail SA, Mowafi HA (2009) Melatonin provides anxiolysis, enhances 
analgesia, decreases intraocular pressure, and promotes better operating 
conditions during cataract surgery under topical anesthesia. Anesth Analg 108: 
1146-1151.
21. Sande PH, Fernandez DC, Marcos HJA, Chianelli MS, Aisemberg J, et al. 
(2008) Therapeutic effect of melatonin in experimental uveitis. Am J Pathol 
173: 1702-1713.
22. Pflugfelder SC, Farley W, Luo L, Chen LZ, de Paiva CS, et al. (2005) Matrix 
metalloproteinase-9 knockout confers resistance to corneal epithelial barrier 
disruption in experimental dry eye. Am J Pathol 166: 61-71.
23. Alarma-Estrany P, Crooke A, Pintor J (2009) 5-MCA-NAT does not act through 
NQO2 to reduce intraocular pressure in New-Zealand white rabbit. J Pineal 
Res 47: 201-209.
24. Loma P, Guzman‐Aranguez A, Pérez de Lara MJ, Pintor J (2015) Diadenosine 
tetraphosphate induces tight junction disassembly thus increasing corneal 
epithelial permeability. Br J Pharmacol 172: 1045-1058.
25. Loma P, Guzman-Aranguez A, de Lara MJP, Pintor J (2015) Diadenosine 
tetraphosphate improves adrenergic anti-glaucomatous drug delivery and 
efficiency. Exp Eye Res 134: 141-147.
26. Chen H (2015) Recent developments in ocular drug delivery. J Drug Target 
23: 597-604.
27. Pintor J (2014) Contact lenses: new devices for nucleotide delivery in ocular 
pathologies. Purinergic Signal 10: 419-420.
28. Alkozi HA, Wang X, de Lara MJP, Pintor J (2017) Presence of melanopsin in 
human crystalline lens epithelial cells and its role in melatonin synthesis. Exp 
Eye Res 154: 168-176.
